XML 12 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 23,278,392 $ 19,136,472
Short-term investments 118,611,601 85,629,412
Accounts receivable 6,237,078 15,821,511
Accounts receivable from affiliated entities 924,677 748,355
Prepaid expenses and other current assets 4,538,843 1,749,059
Prepaid expenses and other current assets from affiliated entities 997,213 1,512,424
Total current assets 154,587,804 124,597,233
Fixed assets, net 18,471,231 9,025,446
Investment in affiliated entity - GeneOne 8,776,603 16,052,065
Investment in affiliated entity - PLS 2,720,045 3,777,510
Intangible assets, net 6,413,792 7,628,394
Goodwill 10,513,371 10,513,371
Other assets 2,197,182 2,113,147
Total assets 203,680,028 173,707,166
Current liabilities:    
Accounts payable and accrued expenses 22,527,486 19,597,787
Accounts payable and accrued expenses due to affiliated entities 782,878 1,072,579
Accrued clinical trial expenses 7,920,045 6,368,389
Common stock warrants 940,341 1,167,614
Deferred revenue 179,523 14,762,720
Deferred revenue from affiliated entities 243,986 407,292
Deferred rent 769,313 446,646
Total current liabilities 33,363,572 43,823,027
Deferred revenue, net of current portion 164,604 317,808
Deferred revenue from affiliated entities, net of current portion 0 86,694
Deferred rent, net of current portion 7,857,879 5,926,424
Deferred tax liabilities 174,793 174,793
Total liabilities 41,560,848 50,328,746
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Preferred stock 0 0
Common stock 90,295 74,062
Additional paid-in capital 663,223,094 556,718,356
Accumulated deficit (501,850,138) (434,838,235)
Accumulated other comprehensive income 559,660 1,327,968
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 162,022,911 123,282,151
Non-controlling interest 96,269 96,269
Total stockholders’ equity 162,119,180 123,378,420
Total liabilities and stockholders’ equity $ 203,680,028 $ 173,707,166